NEW YORK (GenomeWeb News) – BioFire Diagnostics today announced the 510(k) submission of its FilmArray Blood Culture Identification, or BCID, Panel to the US Food and Drug Administration.

The submission follows the successful completion of clinical trials for the panel, which provides automatic results for the most common infectious causes of sepsis. BioFire said that pending clearance from FDA, it anticipates launching the panel in the summer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.